

MedicinesOptimisation intervention brief

Title of Intervention:

Kelhale as the preferred brand of extra-fine beclometasone dipropionate pressurised inhalation solution in adult patients

WHAT?

- Prescribe Qvar[®] inhalers as the relevant strength of Kelhale[®] inhaler.
- Initiate Kelhale® as the preferred brand for any new patients >18 years requiring an extra-fine beclometasone dipriopionate inhaler.

WHY?

- Provides consistency for the patient with less chance of confusion between brands.
- Local hospitals are using Kelhale[®] as their preferred brand.
- Kelhale[®] is one of the brands that provide best value for money.
- Dosing is equivalent to Qvar[®].
- Estimated potential savings for West Hampshire CCG of £100,000 per annum.

WHO?

- Adult (>18years) patients who need to be initiated on beclometasone dipropionate extra-fine particle inhalers.
- Adult (>18years) patients requiring regular repeat prescriptions for Qvar[®].
- Do not switch patients on Qvar[®] Easi-Breath or Autohaler devices
- Kelhale[®] is not licensed in children under 18years

TIPS?

- Review patients' inhaler technique and check for appropriate use of MDI.
- Refer to inhaler information sheet to aid identification of beclometasone containing MDIs.
- The packaging does not make it clear this is a PREVENTER inhaler.

HOW?

- Use search to identify patients >18 years prescribed Qvar[®] on current repeat.
- Switch adult patients requiring regular repeat prescriptions for Qvar[®] inhaler to the relevant strength of Kelhale[®] inhaler according to the process agreed with an individual practice.

SO WHAT?

- All patients will receive a consistent brand of beclomethasone dipropionate inhaler.
- Savings will be realised.

FURTHER INFORMATION

Summary of Product Characteristics

https://www.medicines.org.uk/emc/search?q=kelhale

Appendix: Identification of beclometasone containing metered dose inhalers (MDI)

Extra-fine particle devices: Qvar and Kelhale

(NB. Qvar is also available as Easi-Breath and Autohaler devices)



Standard particle size devices: Clenil modulite and Soprobec



Approved October 2020

Review date: October 2022









